PCVX Stock Analysis: Vaxcyte | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 8.763m USD | 12M Return: 93.5% | US92243G1085 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 51.5M
Warnings
Tailwinds
No distinct edge detected
Seasonality 6.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Vaxcyte, Inc. (NASDAQ: PCVX) is a clinical-stage biotechnology company developing conjugate and novel protein vaccines aimed at preventing or treating bacterial infectious diseases. The company is headquartered in San Carlos, California, was incorporated in 2013, and rebranded from SutroVax, Inc. in May 2020 ahead of its June 2020 IPO.
Its lead candidate, VAX-24, is a 24-valent carrier-sparing pneumococcal conjugate vaccine (PCV) being developed to prevent invasive pneumococcal disease (IPD) in infants. The pipeline extends across VAX-31 (a 31-valent PCV for adults and children), VAX-A1 (Group A Streptococcus), VAX-PG (periodontitis-associated pathogen), VAX-GI (Shigella-related dysentery, preclinical), and VAX-XL, a next-generation PCV.
As a clinical-stage biotech, Vaxcyte generates no commercial product revenue and depends on capital markets and R&D funding to advance its pipeline, with future revenue dependent on regulatory approval and successful commercialization. Conjugate vaccines, the companys core technology, link polysaccharide antigens to carrier proteins to elicit stronger and longer-lasting immune responses than polysaccharide vaccines alone.
- VAX-24 Phase 3 infant data readout looms as key catalyst
- Competition intensifies against Pfizer Prevnar franchise
- Cash burn pressures clinical-stage balance sheet
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.28 > 0.02 and ΔFCF/TA -12.31 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.28 > 3% & CFO -881.2m > Net Income -1.06b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.72 > 1.5 & < 3 |
| Outstanding Shares: last quarter (144.5m) vs 12m ago 6.22% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.41 (Total Current Assets 1.55b - Total Current Liabilities 271.3m) / Total Assets 3.14b |
| B: -0.88 (Retained Earnings -2.76b / Total Assets 3.14b) |
| C: -0.36 (EBIT TTM -1.17b / Avg Total Assets 3.22b) |
| D: 7.25 (Book Value of Equity 2.76b / Total Liabilities 380.2m) |
| Altman-Z'' = 5.00 = AAA |
As of August 08, 2026, the stock is trading at USD 58.07 with a total of 1,296,252 shares traded. Over the past week, the price has changed by +7.38%, over one month by -4.29%, over three months by +12.80% and over the past year by +93.50%.
Current recommended Stop Loss: 54.20 (which is 6.7% or 1.5 ATR below the current price).
Vaxcyte has received a consensus analysts rating of 4.90. Therefore, it is recommended to buy PCVX.
- StrongBuy: 9
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 109 | 87.7% |
P/B = 2.6065
Revenue TTM = 0.0 USD
EBIT TTM = -1.17b USD
EBITDA TTM = -1.14b USD
Long Term Debt = 108.9m USD (estimated: total debt 115.4m - short term 6.51m)
Short Term Debt = 6.51m USD (from shortTermDebt, last quarter)
Debt = 115.4m USD (from shortLongTermDebtTotal, last quarter) (leases 116.3m already included)
Net Debt = -1.37b USD (calculated: Debt 115.4m - CCE 1.49b)
Enterprise Value = 7.39b USD (8.76b + Debt 115.4m - CCE 1.49b)
Interest Coverage Ratio = unknown (Ebit TTM -1.17b / Interest Expense TTM 0.0)
EV/FCF = -8.27x (Enterprise Value 7.39b / FCF TTM -894.1m)
FCF Yield = -12.10% (FCF TTM -894.1m / Enterprise Value 7.39b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 2.36 (Enterprise Value 7.39b / Total Assets 3.14b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 115.4m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -920.6m (EBIT -1.17b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.72 (Total Current Assets 1.55b / Total Current Liabilities 271.3m)
Debt / Equity = 0.04 (Debt 115.4m / totalStockholderEquity, last quarter 2.76b)
Debt / EBITDA = 1.20 (negative EBITDA) (Net Debt -1.37b / EBITDA -1.14b)
Debt / FCF = 1.53 (negative FCF - burning cash) (Net Debt -1.37b / FCF TTM -894.1m)
Total Stockholder Equity = 2.83b (last 4 quarters mean from totalStockholderEquity)
RoA = -33.03% (Net Income -1.06b / Total Assets 3.14b)
RoE = -37.57% (Net Income TTM -1.06b / Total Stockholder Equity 2.83b)
RoCE = -39.61% (EBIT -1.17b / Capital Employed (Equity 2.83b + L.T.Debt 108.9m))
RoIC = -32.04% (negative operating profit) (NOPAT -920.6m / Invested Capital 2.87b)
WACC = 9.21% (E(8.76b)/V(8.88b) * Re(9.33%) + D(115.4m)/V(8.88b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.33% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.82 | Cagr: 12.13%
[DCF] Fair Price = unknown (Cash Flow -894.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -2.29 | # QB: -4
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-09-30): EPS=-1.99 | Chg30d=+7.87% | Revisions=+0% | Analysts=5
EPS current Year (2026-12-31): EPS=-7.93 | Chg30d=+6.49% | Revisions=+0% | GrowthEPS=-40.9% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-7.39 | Chg30d=+0.37% | Revisions=+0% | GrowthEPS=+6.8% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +0% (up=0, down=0)